GSK plc (GSK.L) Tuesday said it has agreed to acquire Aiolos Bio, Inc., a clinical-stage biopharmaceutical company developing treatments for certain respiratory and inflammatory conditions.
The deal includes $1 billion upfront payment and up to $400 million in milestone payments.
The acquisition adds Aiolos' AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, to GSK's respiratory pipeline. AIO-001 is ready to enter Phase 2 study for the treatment of adults with asthma.
AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.